Expert Management of Treatment-Related Symptoms Associated With BCL-2 Inhibitors in Hematologic Malignancies

Get expert guidance on managing adverse events associated with BCL-2 inhibitors in hematologic malignancies using an interactive treatment decision tool to provide expert recommendations on managing key toxicities, then download a patient resource and read an expert authored CME/CNE/CPE-certified text module with downloadable slides.

Share

Program Content

Activities

BCL2  Inhibitor Therapy
Understanding BCL-2 Inhibitor Treatment and Management of Potential Side Effects
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: May 20, 2024

Expires: May 19, 2025

Activities

BCL2AETooL
Interactive Tool for Managing Adverse Events Associated With BCL-2 Inhibitors in Hematologic Malignancies
Tool
Congratulations: You achieved a completion on 04/09/2022

Released: August 23, 2024

Expires: August 22, 2025

Faculty

cover img faculity

Farrukh T Awan, MD, MS, MBA

Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

cover img faculity

Courtney DiNardo, MD, MSCE

Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center
Houston, Texas

cover img faculity

Daniel A. Pollyea, MD, MS

Professor of Medicine
Clinical Director of Leukemia Services
Associate Chief of Clinical Affairs
Robert H. Allen MD Chair in Hematology Research
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

cover img faculity

Caitlin R Rausch, PharmD, BCOP

Clinical Pharmacy Specialist, Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from AbbVie Inc.

AbbVie Inc.